ATRC News and Press, AtriCure Inc. From 02/23/21

AtriCure (ATRC): Q4 Non-GAAP EPS of -$0.18 beats by $0.07; GAAP EPS of -$0.42 misses by $0.13.Revenue of $57.73M (-5.9% Y/Y) misses by $0.23M.Shares -5.03%.Press Release For further details see: AtriCure EPS beats by $0.07, misses on revenue

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced fourth quarter 2020 and full year 2020 financial results. “Despite challenges posed in 2020 as a result of the...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming SVB Leerink 10 th Annual Global Healthcare Conference...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2020 financial results on Tuesday, February 23, 2021. AtriCure ...

AtriCure ([[ATRC]] +0.8%) expects Q4 revenue to decline ~6% Y/Y and ~+5% M/M to ~$57.7M vs. consensus of $58.11M. FY2020 to drop ~11% Y/Y to $206.5M vs. consensus of $206.97M, impacted by the global decline in surgical procedures as a result of the COVID-19 pandemic. “We are pleased wi...

Fourth quarter 2020 worldwide revenue of $57.7 million (U.S. $47.4 million, International $10.3 million) AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced preliminary financ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Expansion includes adolescent patients, as young as 12 years of age, who can benefit from cryo nerve block therapy during surgical procedures involving the chest wall. AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left at...

Reversing the contraction this year, MedTech could outperform in 2021, J.P. Morgan Securities predict, citing the sector’s potential to combine the ‘strong vaccine-driven recovery trade’ with ‘positive underlying sector fundamentals.’ Despite a less bullish ...

AtriCure has expertise in atrial fibrillation and key upcoming infection points that must be considered by investors. We believe the market is unfairly discounting the company's shares based on FDA overhang, however Convergent asset potential alongside the product mix outweigh this. ...